Who owns Aktis Oncology, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of AKTS from SEC Form 13F filings across 113 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 113 institutions disclosed 34.2M shares of Aktis Oncology, Inc. worth $1.10B — about 61.8% of shares outstanding; the largest disclosed holder is MPM BIOIMPACT LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
113
13F holders
$1.10B
value, 2026 filers
61.8%
of shares outstanding (34.2M sh)
52
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of AKTS's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | MPM BIOIMPACT LLC | 4.8M | $155.9M | 9.5% | 8.7% | 0.0% |
| 2 | EcoR1 Capital, LLC | 4.8M | $155.5M | 7.6% | 8.7% | 0.0% |
| 3 | Blue Owl Capital Holdings LP | 3.1M | $99.0M | 14.9% | 5.6% | -2.9% |
| 4 | BlackRock, Inc. | 2.3M | $73.4M | 0.0% | 4.1% | +7.9% |
| 5 | T. Rowe Price Investment Management, Inc. | 2.1M | $66.1M | 0.0% | 3.7% | -3.4% |
| 6 | WELLINGTON MANAGEMENT GROUP LLP | 2.0M | $63.4M | 0.0% | 3.6% | -15.1% |
| 7 | RTW INVESTMENTS, LP | 1.6M | $51.3M | 0.4% | 2.9% | 0.0% |
| 8 | RA CAPITAL MANAGEMENT, L.P. | 1.3M | $42.4M | 0.4% | 2.4% | -12.6% |
| 9 | Jupiter Topco LLCNEW | 1.3M | $42.4M | 0.0% | 2.4% | new |
| 10 | BAKER BROS. ADVISORS LP | 996,351 | $32.1M | 0.2% | 1.8% | 0.0% |
| 11 | Octagon Capital Advisors LP | 960,847 | $31.0M | 2.8% | 1.7% | 0.0% |
| 12 | Merck & Co., Inc. | 952,844 | $30.7M | 5.8% | 1.7% | 0.0% |
| 13 | VANGUARD CAPITAL MANAGEMENT LLC | 817,075 | $26.3M | 0.0% | 1.5% | -2.0% |
| 14 | PRICE T ROWE ASSOCIATES INC /MD/ | 763,499 | $24.6M | 0.0% | 1.4% | -51.2% |
| 15 | TCG Crossover Management, LLCNEW | 696,560 | $22.5M | 0.5% | 1.3% | new |
| 16 | GEODE CAPITAL MANAGEMENT, LLC | 520,737 | $16.8M | 0.0% | 0.9% | +5.9% |
| 17 | EVENTIDE ASSET MANAGEMENT, LLC | 507,000 | $16.3M | 0.2% | 0.9% | 0.0% |
| 18 | Avidity Partners Management LP | 484,200 | $15.6M | 2.5% | 0.9% | +3.3% |
| 19 | STATE STREET CORP | 484,010 | $15.6M | 0.0% | 0.9% | +13.0% |
| 20 | a16z Capital Management, L.L.C. | 415,000 | $13.4M | 0.1% | 0.8% | 0.0% |
| 21 | Alyeska Investment Group, L.P. | 290,000 | $9.3M | 0.0% | 0.5% | 0.0% |
| 22 | FMR LLC | 285,631 | $9.2M | 0.0% | 0.5% | -26.1% |
| 23 | ArrowMark Colorado Holdings LLC | 245,872 | $7.9M | 0.3% | 0.4% | -25.4% |
| 24 | NORTHERN TRUST CORP | 180,575 | $5.8M | 0.0% | 0.3% | +20.8% |
| 25 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 166,842 | $5.4M | 0.0% | 0.3% | +3.0% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.